Tüm Yayınlar
Permanent URI for this communityhttps://hdl.handle.net/20.500.12645/1
Browse
Browsing by Type "Editorial Material"
Now showing 1 - 2 of 2
- Results Per Page
- Sort Options
Publication Metadata only 120-W GreenLight Laser Photoselective Vaporization of Prostate for Benign Prostatic Hyperplasia: Midterm Outcomes REPLY(01.07.2011) Tasci, Ali Ihsan; Sahin, Selcuk; Tugcu, Volkan; Ilbey, Yusuf Ozlem; Luleci, Huseyin; Cicekler, Olcay; Cevik, CemOBJECTIVES To evaluate the safety and efficacy of 120-W high-performance system (HPS) laser photoselective vaporization of the prostate (PVP) in the treatment of patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia. METHODS Two experienced surgeons performed 120-W HPS laser PVP. The baseline characteristics, perioperative data, complications, and postoperative outcomes were evaluated at 3, 6, 12, 24, and 36 months postoperatively. RESULTS A total of 550 consecutive patients, with a mean age of 67.6 years, underwent PVP with a 120-W HPS laser. The mean prostate volume was 72.93 cm(3), with a mean prostate-specific antigen level of 3.57 ng/mL. The mean operative duration and the mean applied energy was 61.3 minutes and 164.06 kJ, respectively. No major complication occurred intraoperatively or postoperatively. The mean follow-up was 17.80 months. Significant improvements were observed postoperatively in the mean International Prostate Symptom Score, quality of life score, maximal urinary flow rate, and postvoid residual urine volume. The mean catheterization time was 18.5 hours. The complications included delayed hematuria in 26 (4.8%), recatheterization in 24 (4.4%), reoperation owing to residual prostatic adenoma in 46 (8.5%), urethral stricture in 19 (3.5%), and bladder neck contracture in 6 (1.1%) patients. CONCLUSIONS PVP with a 120-W HPS laser for benign prostatic hyperplasia has been proved to be a safe and effective procedure for our patients, including those treated with oral anticoagulants. The functional outcome in larger prostates was similar to that in smaller glands. UROLOGY 78: 134-141, 2011. (C) 2011 Elsevier Inc.Publication Metadata only A rare cause of hypertension in childhood: Answers(1.01.2020) Kucuk, Nuran; Abali, Zehra Yavas; Abali, Saygin; Canpolat, Nur; Yesil, Gozde; Turan, Serap; Bereket, Abdullah; Guran, TulayBackground: A novel rapid, accurate, and stability-indicating reversed-phase high performance liquid chromatographic (RP-HPLC) and first derivative spectrophotometric determination were explained for the assay of vortioxetine (VRT) in bulk and pharmaceutical formulations. For RP-HPLC method, optimal separation and determination of VRT were achieved with a Waters Symmetry C-18, (100 x 4.6 mm, 3.5 mu m) analytical column using a mobile phase consisting of methanol:0.05 M potassium dihydrogen phosphate (pH:3.0 +/- 0.05) (30:70, v/v) in isocratic mode with flow rate of 1.3 mL min(-1). Injection volume was 20 mu L. The maximum absorption wavelength of VRT is 225.0 nm; hence, 225.0 nm was studied as the detection wavelength and column at 50 degrees C temperature. The caffeine was used as the internal standard (IS). On the other hand, the first derivative spectrophotometric method for the analysis of vortioxetine was performed by measuring the amplitude at 251.7 and 272.6 nm. Result: The HPLC method was found to be linear in the concentration ranges of 10.0-70.0 mu g mL(-1) with the coefficient value R-2 of 0.9998, and the mean recovery value was 100.7%. Further stability studies were done through exposure of the analyte solutions to various stress conditions: acid, alkali hydrolysis, chemical oxidation, and exposure to UV radiation. For the first derivative spectrophotometric method, linearity was observed in the concentration range 6.0-30.0 mu g mL(-1) (for 237.7 nm R-2 = 0.9999 and for 257.2 nm R-2 = 0.9997). Conclusion: The methods were validated in accordance with ICH guidelines with respect to linearity, accuracy, specificity, limit of detection, precision, and limit of quantification.